OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Ahn on Navigating Among Available Therapeutic Options in Advanced, Unresectable HCC

June 22nd 2021

Daniel H. Ahn, DO, shares how to navigate among the therapeutic options available for patients with advanced, unresectable hepatocellular carcinoma.

Dr. Spira on the Updated Results of the CHRYSALIS Trial in EGFR-Mutant NSCLC

June 22nd 2021

Alexander Spira, MD, PhD, FACP, discusses the updated results of the phase 1 CHRYSALIS trial in EGFR-mutant non–small cell lung cancer.

Dr. Liu on the Rationale for the ARROW Trial in RET Fusion+ NSCLC

June 22nd 2021

Stephen Liu, MD, discusses the rationale for the ongoing phase 1/2 ARROW trial in RET fusion–positive non–small cell lung cancer.

Dr. Abedin on Managing Cardiac Toxicities With Acalabrutinib vs Ibrutinib in CLL

June 22nd 2021

Sameem Abedin, MD, discusses managing cardiac toxicities with acalabrutinib vs ibrutinib in patients with chronic lymphocytic leukemia.

Dr. Pennell on Understanding the Cost-Effectiveness of Osimertinib in NSCLC

June 22nd 2021

Nathan A. Pennell, MD, PhD, discusses the importance of understanding the cost-effectiveness of osimertinib in non–small cell lung cancer.

Dr. Simons on Racial Disparities Reported in Luminal Breast Cancer

June 22nd 2021

Yael Simons, MD, discusses the racial disparities seen in African Americans patients with luminal breast cancer.

Dr. Garber on the Efficacy of Adjuvant Olaparib in High-Risk, HER2-Negative Breast Cancer

June 22nd 2021

Judy Garber, MD, MPH, discusses the efficacy of adjuvant olaparib in patients with high-risk, HER2-negative breast cancer, as demonstrated in the phase 3 OlympiA trial.

Dr. Abedin on Frontline Treatment Considerations in CLL 

June 21st 2021

Sameem Abedin, MD, discusses frontline treatment considerations for patients with chronic lymphocytic leukemia.

Dr. Nadeem on the Emergence of Quadruplet Regimens in Multiple Myeloma

June 21st 2021

Omar Nadeem, MD, discusses the emergence of quadruplet regimens in multiple myeloma.

Dr. Michaelis on Safety Considerations With Venetoclax/Azacitidine in AML

June 21st 2021

Laura C. Michaelis, MD, discusses safety considerations with the combination of venetoclax and azacitidine in acute myeloid leukemia.

Dr. Jones on the Clinical Utility of Pembrolizumab in MSI-H CRC

June 21st 2021

Jeremy C. Jones, MD, discusses the clinical utility of pembrolizumab in microsatellite instability–high colorectal cancer.

Dr. Kiladjian on the Potential Utility of Momelotinib in Myelofibrosis

June 21st 2021

Jean-Jacques Kiladjian, MD, PhD, discusses, the potential utility of momelotinib in myelofibrosis.

Dr. Abedin on the Clinical Significance of Undetectable MRD in CLL

June 21st 2021

Sameem Abedin, MD, discusses the clinical significance of undetectable minimal residual disease status in chronic lymphocytic leukemia.

Dr. Klein on the Rationale to Evaluate VERU-111 in mCRPC

June 21st 2021

Eric Klein, MD, discusses the rationale to evaluate VERU-111 in metastatic castration-resistant prostate cancer.

Dr. Mascarenhas on Potential for Pacritinib to Address an Unmet Need in Myelofibrosis

June 17th 2021

John O. Mascarenhas, MD, discusses the potential for pacritinib to address an unmet need in the treatment of patients with myelofibrosis.

Dr. Verstovsek on the Efficacy of Pacritinib in Myelofibrosis

June 17th 2021

Srdan Verstovsek, MD, PhD, discusses the efficacy demonstrated with pacritinib in the treatment of patients with myelofibrosis.

Dr. Sperling on the Rationale to Evaluate Cellular Therapy in Multiple Myeloma

June 17th 2021

Adam Sperling, MD, PhD, discusses the rationale to evaluate cellular therapy in multiple myeloma.

Dr. Bekaii-Saab on the Uptake of Precision Medicine in CRC

June 17th 2021

Tanios S. Bekaii-Saab, MD, FACP, discusses the uptake of precision medicine in colorectal cancer.

Dr. Ahn on the Utility of Atezolizumab/Bevacizumab in HCC

June 17th 2021

Daniel H. Ahn, DO, discusses the utility of atezolizumab in combination with bevacizumab in hepatocellular carcinoma.

Dr. Davies on Future Research Directions With Isatuximab in Multiple Myeloma

June 16th 2021

Faith Davies, MD, discusses future research directions with isatuximab in the treatment of patients with multiple myeloma.